Active	Status	Sponsor type	Region	Phase	Filter
3 Active 4 Inactive 7 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Solymbic (adalimumab biosimilar) / Amgen
2021-000542-18: A Study to Investigate the Impact of Switching Between ABP 501 and Adalimumab for the Treatment of Subjects with Moderate to Severe Plaque Psoriasis	Not yet recruiting	3	414	Europe	ABP 501-HCF, Solution for injection in pre-filled syringe, Humira	Amgen Inc., Amgen Inc.	Moderate to Severe Plaque Psoriasis, Moderate to Severe Plaque Psoriasis, Diseases [C] - Immune System Diseases [C20]
NCT05995691: Study to Determine the Pharmacokinetic (PK) Bioequivalence of ABP 501 and Adalimumab (Humira®) in Healthy Adult Japanese Participants	Completed	1	179	NA	ABP 501, Adalimumab, Humira®	Amgen	Healthy Volunteers	12/15	12/15
NCT05909852: A Study Comparing the Pharmacokinetics (PK) of ABP 501 40 mg/0.4 mL (ABP 501-HCF) and ABP 501 40 mg/0.8 ml (ABP 501-LCF) in Healthy Adult Participants	Completed	1	372	US	ABP 501-HCF, ABP 501-LCF	Amgen	Adalimumab	11/21	11/21